Total Funding
78
42
Total FundingSeries B raised
Growth Score
-5 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
29991
Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.
David Neafus: CFOPast Role: Triana Biomedicines, CFO- Frederic Guerard: President and Chief Executive OfficerPast Role: Opthea, Chief Executive Officer
About the Company
Qlaris Bio is a clinical stage biotechnology company that develops innovative first-in-class therapies for patients suffering from serious and debilitating ophthalmic diseases. Qlaris Bio is exploring novel mechanisms of action to address episcleral venous pressure (EVP), the largest component of intraocular pressure (IOP), to reduce the risk of
blindness in glaucoma, including Primary Open Angle Glaucoma and Normal tension Glaucoma.
Women Founded
